SIRRT (Selinexor in Relapsed/Refractory Richters Transformation)

• Research type

  Research Study

• Full title

  A Phase 2 Study of the Safety and Anti-tumor Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Refractory and/or Relapsed Richter’s Transformation (RT).

• IRAS ID

  158483

• Contact name

  Anna Schuh

• Contact email

  anna.schuh@nhs.net

• Eudract number

  2014-001240-38

• Research summary

  This study aims to assess the safety and efficacy of the study drug Selinexor (KPT-330)in patients with refractory (ie cancer that does not respond to treatment) and or relapsed (ie return of the cancer after a period of improvement)Richter's Syndrome.

• REC name

  South Central - Oxford B Research Ethics Committee

• REC reference

  14/SC/1284

• Date of REC Opinion

  6 Feb 2015

• REC opinion

  Further Information Favourable Opinion